- Home
- JRS vs PRQR Comparison
JRS vs PRQR Comparison
Compare JRS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- PRQR
- Stock Information
- Founded
- JRS 2001
- PRQR 2012
- Country
- JRS United States
- PRQR Netherlands
- Employees
- JRS N/A
- PRQR N/A
- Industry
- JRS Finance/Investors Services
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- PRQR Health Care
- Exchange
- JRS Nasdaq
- PRQR Nasdaq
- Market Cap
- JRS 231.7M
- PRQR 224.4M
- IPO Year
- JRS N/A
- PRQR 2014
- Fundamental
- Price
- JRS $8.02
- PRQR $2.29
- Analyst Decision
- JRS
- PRQR Strong Buy
- Analyst Count
- JRS 0
- PRQR 8
- Target Price
- JRS N/A
- PRQR $8.88
- AVG Volume (30 Days)
- JRS 86.6K
- PRQR 396.7K
- Earning Date
- JRS 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- JRS 8.87%
- PRQR N/A
- EPS Growth
- JRS N/A
- PRQR N/A
- EPS
- JRS N/A
- PRQR N/A
- Revenue
- JRS N/A
- PRQR $20,129,184.00
- Revenue This Year
- JRS N/A
- PRQR N/A
- Revenue Next Year
- JRS N/A
- PRQR N/A
- P/E Ratio
- JRS N/A
- PRQR N/A
- Revenue Growth
- JRS N/A
- PRQR 8.65
- 52 Week Low
- JRS $5.95
- PRQR $1.07
- 52 Week High
- JRS $8.00
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- JRS 45.75
- PRQR 54.27
- Support Level
- JRS $8.00
- PRQR $2.08
- Resistance Level
- JRS $8.17
- PRQR $2.54
- Average True Range (ATR)
- JRS 0.10
- PRQR 0.14
- MACD
- JRS -0.02
- PRQR 0.02
- Stochastic Oscillator
- JRS 22.41
- PRQR 59.38
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.